2026 жылында Италияда миеломаның емдеу бойынша ең жақсы бағалар мен клиникалар туралы біліңіз

Standard first-line treatment for multiple myeloma in Italy follows European Society for Medical Oncology protocols. Care is tailored to transplant eligibility. Eligible patients receive induction therapy with triplets or quadruplets. This is followed by autologous stem cell transplantation and lenalidomide maintenance.

• Transplant-eligible induction: Standard quadruplet regimens include subcutaneous daratumumab plus bortezomib, thalidomide, and dexamethasone.
• Transplant-ineligible primary: Patients usually receive a triplet of daratumumab, lenalidomide, and dexamethasone continuously.
• Specialized facilities: Major centers like San Raffaele in Milan offer advanced cell and gene therapies.
• Specialist oversight: Experts like Dr. Fabio Ciceri manage complex cases using multidisciplinary hematological approaches.

Bookimed Expert Insight: Italian academic centers like San Raffaele specialize in high-volume transplant protocols. Dr. Jacopo Peccatori oversees approximately 90 allogeneic transplants annually at one of the country's largest units. This level of institutional experience is vital for managing the transition from induction to transplant. Patients should focus on clinics that combine clinical research with daily oncological practice for better access to trials.

Patient Consensus: Patients emphasize the importance of confirming transplant eligibility early to set clear expectations for the treatment path. Many note that specialized hematology units provide much smoother transitions between the intense induction phase and long-term maintenance therapy.

Italy offers EMA-approved treatments for relapsed or refractory multiple myeloma, including CAR T-cell therapy and bispecific antibodies. The Italian Medicines Agency (AIFA) reimburses advanced options like Carvykti and Tecvayli. Specialized IRCCS-accredited research hospitals in Milan and Rome manage complex therapy sequences and transplants.

• Advanced immunotherapies: AIFA reimburses Carvykti and bispecific antibodies like Elrexfio for heavily pre-treated patients.
• Triplet regimens: Combinations including carfilzomib, isatuximab, or pomalidomide target lenalidomide-refractory multiple myeloma cases.
• Specialized centers: San Raffaele in Milan performs approximately 90 allogeneic transplants every year.
• Salvage transplants: Eligible patients may receive a second autologous stem cell transplant after long remissions.

Bookimed Expert Insight: While many countries separate research from clinical care, Italian IRCCS-accredited centers like San Raffaele integrate both. This allows patients earlier access to experimental cell and gene therapy protocols. Dr. Fabio Ciceri and Dr. Jacopo Peccatori oversee units that prioritize these high-volume, research-driven approaches for complex relapses.

Patient Consensus: Patients find that choosing a treatment depends mostly on which drugs they have already tried. They note that specialized centers are essential for accessing the newest clinical trials and advanced immunotherapies.

Italy hosts leading myeloma centers recognized for academic research and advanced cellular therapies. Facilities like San Raffaele in Milan and Policlinico Sant Orsola in Bologna provide high-volume stem cell transplantation. These research hospitals integrate molecular diagnostics to track minimal residual disease and guide targeted therapy.

• Specialized accreditation: IRCCS certification signifies institutions combining high-level medical care with scientific research.
• Transplant volume: San Raffaele performs over 90 allogeneic and autologous stem cell transplants annually.
• Advanced diagnostics: Centers use advanced molecular biology and functional imaging to evaluate treatment response.
• Cellular immunotherapy: Leading hospitals provide access to CAR T-cell protocols and experimental targeted regimens.

Bookimed Expert Insight: Data shows that San Raffaele stands out not just for volume but for leadership in gene therapy innovation. Dr. Jacopo Peccatori and Prof. Fabio Ciceri oversee one of the largest transplant units in Italy. With over 300,000 patients treated annually across the hospital, these specialists maintain rare expertise in managing complex myeloma cases within a multi-disciplinary research setting.

Patient Consensus: Patients emphasize that success depends on finding a dedicated hematology team rather than just a general oncology clinic. Many suggest using major university centers in Milan or Bologna for the primary treatment plan while coordinating routine monitoring locally.

CAR T-cell therapy is accessible for multiple myeloma patients in Italy at accredited research hospitals. The Italian Medicines Agency provides reimbursement for therapies like Carvykti. Eligible patients typically have relapsed or refractory disease. They must have completed at least one prior line of therapy.

• Provider accreditation: Treatment occurs at IRCCS-accredited research hospitals like San Raffaele.
• Clinical lead: Specialized hematology units manage complex cell and gene therapy protocols.
• Eligibility age: Fit patients up to 75 years may qualify for treatment.
• Specific criteria: Patients must show resistance to lenalidomide to meet funding requirements.

Bookimed Expert Insight: San Raffaele in Milan handles over 8,400 operations annually and operates one of the largest transplant units. Patients should target these high-volume centers because they manage 90+ allogeneic transplants every year. This massive caseload ensures the medical team is highly proficient in handling immune responses like Cytokine Release Syndrome. Established centers often have the specialized infrastructure needed to reduce the time between cell collection and infusion.

Patient Consensus: Patients emphasize that access depends on being at a high-volume center rather than a local clinic. Many recommend asking about a bridging treatment plan early to stay stable during the weeks required to manufacture the modified T-cells.

The Italian National Health Service (SSN) does not cover planned myeloma treatment for short-term travelers. Coverage requires formal residency or European Health Insurance Card (EHIC) eligibility for medically necessary care. Non-EU visitors typically pay out-of-pocket at private facilities or state-affiliated research hospitals.

• EU citizenship: EHIC holders access urgent, necessary oncology care in public hospitals.
• Urgent care: Emergency stabilization is provided via the 118 service regardless of citizenship.
• Private treatment: Non-EU travelers must pay for scheduled chemotherapy or stem cell therapy.
• Administrative requirements: Accessing the public system requires registration and a doctor prescription.
• Specialized centers: Facilities like San Raffaele in Milan provide self-pay oncohematology services.

Bookimed Expert Insight: While public coverage is restricted for travelers, Italy hosts highly specialized research institutions like San Raffaele that manage complex cases. Dr. Jacopo Peccatori at San Raffaele oversees 90 allogeneic transplants annually. Patients often choose these IRCCS-accredited centers for private care. This allows them to bypass provincial administrative hurdles while accessing advanced clinical trials for multiple myeloma.

Patient Consensus: Patients note that administrative eligibility is the primary barrier to care rather than medical availability. They emphasize bringing detailed pathology reports and current medication lists to facilitate advice from Italian clinicians during private consultations.

Minimal Residual Disease (MRD) testing in Italy serves as a precision tool for risk stratification. It determines stem cell transplant necessity and guides therapy intensity. Centers use Next-Generation Flow or Sequencing to identify trace cancer cells. Results help clinicians personalize maintenance duration and identify early relapse risk.

• Risk stratification: MRD-positive results categorize patients as high-risk, often triggering allogeneic transplants.
• Preemptive intervention: Rising MRD levels act as an early warning for immediate immunotherapy.
• Treatment de-escalation: Sustained MRD negativity allows doctors to safely pause or reduce maintenance drugs.
• Trial matching: Clinics use MRD status to match patients with novel combination therapy trials.

Bookimed Expert Insight: Italian hematology units like San Raffaele emphasize research-driven care through IRCCS accreditation. While many seek MRD testing for immediate shifts, our data shows Italian specialists like Dr. Jacopo Peccatori prioritize long-term durability. They often confirm MRD status over multiple intervals before modifying maintenance. This conservative approach safely prevents premature treatment changes that could lead to early relapse.

Patient Consensus: Patients find that a negative MRD result provides significant emotional relief and often signals a deeper response. However, many note that Italian doctors rarely stop treatment based on one test, preferring to weigh results against overall clinical symptoms.

Patients can enroll in multiple myeloma clinical trials in Italy through specialized research hospitals. The Italian Medicines Agency (AIFA) regulates these studies under European Union standards. Major centers participate in European Myeloma Network trials. Access requires matching specific eligibility and genetic criteria.

• Research accreditation: IRCCS-accredited centers like San Raffaele combine clinical care with active research.
• Specialized leadership: Principal investigators like Dr. Fabio Ciceri lead gene and cell therapy trials.
• Northern hubs: Trial density is highest in Lombardy, specifically in cities like Milan.
• Free coverage: Experimental drugs and related trial care are provided without patient costs.

Bookimed Expert Insight: Institutional volume is a strong indicator of trial availability in Italy. San Raffaele performs over 52,000 operations annually and holds specific IRCCS research accreditation. Choosing a center with both high patient volume and dedicated hematology research units often increases the chance of finding open recruitment for innovative cell therapies.

Patient Consensus: Patients note that travel logistics are often the biggest challenge. Finding a trial is only the first step. You must also manage frequent visits for blood tests and scans at the specific study center.